Clinical and immunological analysis on the effect of LEM in the adoptive immunotherapy using autologous activated lymphocytes in patients with incurable cancer

Clinical and immunological analysis on the effect of LEM in the adoptive immunotherapy using autologous activated lymphocytes in patients with incurable cancer - LEM on AIT for Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012283

Enrollment

Registered

2013-12-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incurable cancer

Interventions

LEM 1800mg/day, twice a day, orally, 4weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically-defined panreatic cancer 2) Measurable lesion 3) on-going AIT 4) Age 20-80 5) PS 0-2 6) Estimated prognosis >= 3 months 7) Sufficient organ function WBC>4,000/mm3, <12,000/mm3 NE>2,000/mm3 PLT>100.000/mm3 Hg>10.0g/dl GOT/GPT<Normal range x 2 Bil<1.5mg/dl Creat<1.5mg/dl 8) Written informed consent 9) No pregnancy

Exclusion criteria

Exclusion criteria: 1) Autoimmune disease 2) Uncontrollable complications including infection, diabetes, hypertension, ischemic heart disease, cerebral infarction, interstitial pneumonitis, cancer pain 3) Pregnancy 4) Allergy 5) General symptoms including dyspnea, jaundice, edema, effusions, clamp, paralysis, fracture, difficult for out-patient 6) Steroid or immunosuppressive agents 7) Other unacceptable reasons

Design outcomes

Primary

Measure	Time frame
Immunological activity	—

Secondary

Measure	Time frame
QOL, safety	—

Countries

Japan

Contacts

Public ContactYoshiyuki YAMAGUCHI

Kawasaki Medical School Department of Clinical Oncology

shogo@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026